Michael Blaiss, MD

Allergist, Executive Medical Director of the American College of Allergy, Asthma, and Immunology

[Peter Mallouk @PeterMallouk]

The average US family health insurance premium has increased from $6,000 in 2000 to $21,000 in 2022. That’s a 249% increase, or 5.8% per year, more than double inflation.

The biggest beneficiaries of this massive increase in costs: health insurance companies. UnitedHealth (largest US insurer) is up 4,120% since 2000 vs. 340% gain for the S&P 500.

[Michael Blaiss, MD @wheezemd]

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues | BioSpace https://t.co/J5ZJswjJ8z #jobs

[Michael Blaiss, MD @wheezemd]

U.S. FDA declines to approve Eli Lilly's drug to treat eczema https://t.co/UC0THbYSW4

[Michael Blaiss, MD @wheezemd]

Vaping increases risk of asthma in adolescents even without any tobacco smoking https://t.co/DLT273698p

[Annals of Allergy, Asthma & Immunology @AnnalsAllergy]

With significant overlap between allergic rhinitis & chronic rhinosinusitis, it's important for primary care clinicians, allergists & otolaryngologists to appreciate various management approaches

Excellent review re: surgical management of rhinosinusitis:
https://t.co/2TMO4CS9gi

[Annals of Allergy, Asthma & Immunology @AnnalsAllergy]

Looking for a current, comprehensive, and fantastic review on allergic fungal sinusitis?

We've got you covered in our September issue:

https://t.co/2fEGSCZZow

[Annals of Allergy, Asthma & Immunology @AnnalsAllergy]

This recent editorial offers important thoughts for all of us to consider regarding the rising costs of prescription medication
#MedTwitter

https://t.co/S5AIRYFcco

[Michael Blaiss, MD @wheezemd]

Nasal spray alternative to EpiPen suffers setback as FDA seeks fresh study https://t.co/ZxzOxBRwGb

[Michael Blaiss, MD @wheezemd]

Protecting children from poor air quality https://t.co/LFaCAZ5uR6 via @csmottpoll

[Michael Blaiss, MD @wheezemd]

Leading asthma groups tackle definition of clinical remission in treatment of asthma https://t.co/Vw38WA5r6U via @medical_xpress

[Michael Blaiss, MD @wheezemd]

FDA Reviewers Say OTC Decongestant Doesn't Work https://t.co/3FZCIcrr5h

[Michael Blaiss, MD @wheezemd]

https://t.co/4r8LGwAPQ4

[Healio Allergy and Asthma @HealioAllergy]

#Immunotherapy improved bronchial epithelial expression of IFN-beta and IFN-lambda while decreasing IL-33, said researchers at Bispebjerg Hospital. Also, Dr. Michael Blaiss of @wheezemd and Dr. Jay Lieberman of @UTHSCMedicine share their Perspectives.
https://t.co/iS197UJIwd

[Michael Blaiss, MD @wheezemd]

Moving to Threads @wheezemd1. Follow me there.

[Michael Blaiss, MD @wheezemd]

https://t.co/Ag7jk8qpeb

[Michael Blaiss, MD @wheezemd]

Alladapt looks to advance food allergy drug to Phase III https://t.co/VJXVlGqgZv via @fwpharma

[Michael Blaiss, MD @wheezemd]

Blueprint's Ayvakit gets FDA nod for indolent systemic mastocytosis https://t.co/zJFf3Mff4x via @fwpharma

[STAT @statnews]

Medicare Advantage plans are using algorithms to cut off care for seniors in need. Read previous reporting from @bobjherman and @caseymross https://t.co/TojVvgwWXn

[Michael Blaiss, MD @wheezemd]

‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients https://t.co/ov3M1AA9Mx via @statnews. Just when you think it can’t get any crazier.

[Integrity CE, LLC @IntegrityCE]

Direct consequences of poorly controlled AR/C include:
💤 Sleep loss leading in daytime fatigue
↘️ Decreased quality of life
➕ More

View this pediatric allergic rhinitis activity w/ @wheezemd & Erin Tomlin, MD, FAAP to earn 🆓 #CME: https://t.co/1WMlu1lvUH
#MedEd #FOAMed